Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 17, 2016

View Archived Issues

Proteostasis Therapeutics announces pricing of initial public offering

NF-kappaB inhibition reduces symptoms in mouse model of Rett syndrome

FKBP5 found to be involved in chronic pain in mouse models

Novartis patents antibacterial quinolone derivatives

Nanjing Sanhome reports compounds for the treatment of HCV infections

Ocular Therapeutix outlines phase III development plans for OTX-TP

Zilretta meets primary endpoint in pivotal phase III trial in patients with knee osteoarthritis

Gabra-3 overexpression increases breast cancer metastasis

Beta cells encapsulated in optimized alginate maintain normoglycemia in mouse model of diabetes

Galapagos initiates phase II program of GLPG-1837 in cystic fibrosis

FDA grants breakthrough therapy designation for durvalumab

Remedy Pharmaceuticals' Cirara obtains two FDA orphan designations

Phase II study of TNX-201 misses primary endpoints

Biota Pharmaceuticals' BTA-585 granted FDA fast track designation

Kevetrin demonstrates safety and tolerability in phase I study in solid tumors

Apogenix receives grant for immuno-oncology candidate and companion diagnostic

Lipocine reports topline results from study of LPCN-1107

Zepatier available in U.S.

Eisai and Sysmex to codevelop dementia diagnostics

Sernova receives initial funds for development of severe hemophilia A therapy

Carmot Therapeutics and Amgen extend research collaboration

BIND and Synergy to collaborate on Accurin research

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Kymera’s IRF5 degrader shows potential in IBD treatment
BioWorld Science
At the recently concluded Digestive Disease Week, researchers from Kymera Therapeutics Inc. presented preclinical efficacy data on KT-579, a selective oral IRF5...